Navigation Links
Chronic Kidney Disease Growing Globally
Date:6/26/2008

Researchers urge countries to make condition a public health priority

THURSDAY, June 26 (HealthDay News) -- The already high worldwide rate of chronic kidney disease (CKD) is increasing, and the fact it raises a person's risk of death should make the disease a public health priority, say Taiwanese researchers.

They analyzed data on 462,293 people in Taiwan over age 20 who took part in a standard medical screening program in 1994. The participants were observed for 13 years, with a median follow-up of 7.5 years.

The 56,777 (12 percent) people with CKD were 83 percent more likely to die from all causes and twice as likely to die from cardiovascular causes than those without CKD, the study found. Almost 40 percent of deaths in the CKD group occurred before age 65.

Of the deaths in the entire study group, 10.3 percent were attributable to CKD, but this figure increased to 17.5 percent among people with low socioeconomic status. The rate of CKD was higher among people with low socioeconomic status (19.8 percent) than among those with high socioeconomic status. Of those with CKD, only 3.54 percent were aware of their condition. In the United States, that figure is 10 percent.

Interestingly, the researchers also found that people who regularly used Chinese herbal medicines had a 20 percent increased risk of developing CKD.

The number of people in the study affected by CKD was several times more than that for diabetes, and more than half the number affected by high blood pressure.

The study was published in this week's issue of The Lancet.

Under diagnosis and under treatment of CKD is a worldwide issue, the researchers said.

"The high prevalence and its associated all-cause mortality, especially in people with low socioeconomic status, make reduction of CKD a public health priority. Promotion of its recognition through the general public knowing their GFR [glomerul
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New research shows how chronic stress worsens neurodegenerative disease course
2. Katie Lee Joel to Conduct Cooking Demonstration for Local Patients With Chronic Kidney Disease
3. Study identifies key player in the bodys immune response to chronic stress
4. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
5. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
6. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
7. Link Between Chronic Pain and Insomnia Uncovered at PAINWeek 2007
8. Methadone and systematic follow-up: the best solution for managing chronic pain
9. NASN Joins Partnership to Fight Chronic Disease
10. Stomach Virus a Culprit in Chronic Fatigue Syndrome
11. Chronic fatigue syndrome linked to stomach virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...RNewswire/ -- BAPTIST HEALTH, a six-hospital,syst...gest health system, has,expanded its use of Clini...,solution that enabled the system,s pharmacists to...ve more than $1 million. , "Data we collect...hat,CareFocus prompts approximately half of the p...
(Date:12/4/2008)...se seen with standard dose of daunorubicin, study ...ws) -- A high dose of the chemotherapy drug daunor...usly untreated acute myeloid leukemia (AML), preli...tional Cancer Institute (NCI) show. , AML is a ...cluded 633 patients, aged 16 to 60, who were rando...
(Date:12/4/2008)...s Leaders of Virginia, Maryland and D.C. AIDS Offi...wswire/ -- Nationally, Washington, D.C. ranks firs...C., 82 percent are African American. In an effort...the South, today,s Living Quilt roundtable at the ...e leaders of the Virginia, Maryland and District o...
(Date:12/4/2008)...his December, and on the eve of its 35th Anniversa...unch an integrated Season of Giving marketing camp... long way. The initiative, designed to drive perso...harity and its three core programs: Ronald McDonal...d McDonald Care Mobile. , ...
Breaking Medicine News(10 mins):Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 3Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 3
...gs from a recent study researchers say, the ancien...cal application. Lymphoma patients// who took part...n those in a control group. The study was conducte...ther undergoing treatment or who had concluded tre...
...extended exposure to sunlight may lead to age-rela...egeneration an eye // disorder that can cause blin...ts for five years and more than 2,700 patients for...86 years old. Participants who reported being in t...
...s( DVT ) is a blood clot that develops deep in the...lung. // People who require prolonged bed rest ar... blood circulation ,especially patients in intensi...a serious risk for DVT. Recent studies have shown ...
...w individuals in lower socioeconomic groups, as me...ul days than those with // higher socioeconomic st...rger impact on their health. While those with more...y are not as affected by it. For the study, more t...
Other Medicine News:
(Date:12/2/2008)...wire-FirstCall/ -- Biopure Corporation,(Nasdaq: ...l Research Center,(NMRC) has submitted to the Foo...gational new drug (IND) application to conduct a c... Hemopure(R) [hemoglobin glutamer - 250 (bovine)],...uma patients. The study is,entitled "Operation Re...
(Date:12/2/2008).../ -- Horizon Therapeutics, Inc., a,privately held...wo pivotal,Phase 3 trials evaluating its lead inv...primary endpoints. HZT-501, a novel, proprietary f...n and famotidine, demonstrated a,statistically si...dal,anti-inflammatory drug (NSAID)-induced upper ...
(Date:12/1/2008)...2 A study has found tha...ique for imaging the breast, is not affected by ei...two factors that limit the effectiveness of standa...s will be presented today at the annual meeting of... , , "The ability of PEM to detect cancer ...
(Date:12/1/2008)...- S*BIO Pte Ltd today announced the initiation of ... orally-active JAK2 inhibitor, in leading medical ...opathic myelofibrosis (CIMF). , , The tria...ity of SB1518 in patients with CIMF and is expecte... the study will assess the safety profile and eval...
Breaking Medicine Technology:U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Minorities More Likely to Die in ER 27526 1Minorities More Likely to Die in ER 27526 2Minorities More Likely to Die in ER 27526 3Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 1Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 1Douglas Oberhelman Elected to Lilly Board of Directors 8390 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 3Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 1Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 2
...DGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - Combin... preliminary results of,a phase 2 clinical trial s...prednisolone and the antidepressant paroxetine),an...oid arthritis,(RA). This trial served two importan...t of 3mg of prednisolone alone (a very low dose),i...
...Y, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek,P...sentation of,positive Phase 2 clinical data demons...ntial for INO-1001 as a preventative agent for,car...n subjects,with acute ST-elevated myocardial infar...nary intervention. The presentation was,made in a ...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
Medicine Products: